Newsroom

東京--(BUSINESS WIRE)--（ビジネスワイヤ） -- キオクシア株式会社は、8月4日から8月6日まで米国カリフォルニア州サンタクララで開催される「FMS: the Future of Memory and Storage」に出展します。AIアプリケーション向けにGPUによるダイレクトアクセスと最大1,000万IOPS注1の高速ランダムリードを実現するSuper High IOPS SSD「KIOXIA GP1シリーズ」を含む、フラッシュメモリおよびSSD技術がもたらす次世代AIインフラへの貢献について紹介します。次世代AIインフラに求められる性能、拡張性および電力効率の向上を実現する最新のイノベーションを基調講演、エグゼクティブパネルディスカッション、技術セッション、技術デモンストレーションを通じて提案します。 キオクシアは、先日発表したKIOXIA CM10シリーズPCIe® 6.0エンタープライズSSDおよびKIOXIA NX1シリーズSSDを展示します。両シリーズは直接液冷（DLC: Direct Liquid Cooling）方式に対応し、 AIや最新のデータセ...

TOKYO--(BUSINESS WIRE)--Kioxia will showcase the innovations driving the performance, scalability, and efficiency required for next-generation AI infrastructure at FMS 2026....

MEUDON, Frankrijk--(BUSINESS WIRE)--In een context van toenemende samenwerking tussen Europese landen om de gezamenlijke beveiliging te verbeteren, heeft het Roemeense General Directorate for Armaments onlangs een belangrijke overeenkomst ondertekend met het Franse DGA (Direction Générale de l’Armement) om twaalf Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars aan te kopen. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshu...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Computershare Trustees (Jersey) Limited as trustee of the Schroders Employee Benefit Trust (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. Fo...

SAN DIEGO--(BUSINESS WIRE)--LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,...

LAUSANNE, Switzerland & SAN JOSE, Calif.--(BUSINESS WIRE)--Logitech G Streamlabs today announced Network Boost, a new mobile feature for Streamlabs Ultra that helps creators improve stream reliability by combining multiple internet connections using the devices they already own. As IRL streaming skyrockets, with Twitch viewers consuming over 391 million hours of IRL content last year alone, unstable cellular connections on crowded convention floors or city streets remain a massive barrier. Hist...

SENDAI, Japan--(BUSINESS WIRE)--Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existi...

PARIS--(BUSINESS WIRE)--Evexta Bio S.A., une société d'oncologie de précision fondée par Truffle Capital (fondateur d'Abivax et de Carvolix) et consacrée à la découverte et au développement de thérapies ciblées, annonce aujourd'hui la signature d’un contrat de collaboration clinique et d’approvisionnement afin d’effectuer une étude de phase 1b associant son principal candidat médicament, le rupitasertib, avec un produit en développement de Roche, le giredestrant, un dégradateur sélectif des réc...

PARIS--(BUSINESS WIRE)--Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-m...

CAMBRIDGE, England--(BUSINESS WIRE)--Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologis...